Please activate JavaScript!
Please install Adobe Flash Player, click here for download

Cloettapreis_2004_Nr_32

KEY PUBLICATIONS Tuberculosis 1. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M.J., Matter L., Schopfer K., Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet, 341:647–650, 1993. 2. Takiff H., Salazar L., Guerrero C., Philipp W., Huang W.M., Kreiswirth B., Cole S.T., Jacobs W.R. Jr., Telenti A. Cloning and nucleotide sequence of Mycobacterium tuber- culosis gryA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 38:773–780, 1994. 3. Telenti A., Philipp W., Sreevatsan S., Bernasconi C., Stockbauer K. E., Wieles B., Musser J. M., and Jacobs W. R. Jr.: The emb operon, a unique gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nature Med. 3:567–570, 1997. 4. Telenti A., Southworth M., Alcaide F., Daugelat S., Jacobs W.R. Jr., Perler F.B. The Mycobacterium xenopi GyrA protein splicing element: characterization of a minimal intein. J. Bacteriol 179:6378–6382, 1997. 5. Klabunde T., Sharma S., Telenti A., Jacobs W.R. Jr., Sacchettini J.C. Crystal structure of GyrA intein from Mycobacterium xenopi reveals structural basis of protein splicing. Nature Struct Biol 5:31–6, 1998. HIV 1. Peters S., Muñoz M., Yerly S., Sanchez-Merino V., Lopez Galindez C., Perrin L., Larder B., Cmarko D., Fakan S., Meylan P., Telenti A. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by HIV-1 p6Gag. J Virol 75:9644–9653, 2001. 2. Bleiber G., Munoz M., Ciuffi A., Meylan P., Telenti A. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication and protein maturation of antiretroviral drug-resistant HIV-1. J Virol 75:3291–3300, 2001. 3. Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.P., Decosterd L.A., Furrer H., Opravil M., Pantaleo G., Retelska D., Ruiz L., Schinkel A.H.,Vernazza P., Eap C.B., Telenti A. Response to antiretroviral therapy in HIV-infected individuals carrying allelic variants of the multidrug resistant transporter MDR1, a pharmacogenetics study. Lancet 359:30–36, 2002. 14

Seitenübersicht